Aquavit Life Sciences, Inc. announced plans to invest in a new R&D and manufacturing facility in Daegu, South Korea.
Aquavit will build a facility that is compliant with US FDA regulations for current good manufacturing practices (cGMP). Phase 1 of the project will be a 10,000 sq. ft. space equipped with an ISO 5 class cleanroom under ISO 14644-1 classification. Aquavit signed a 5 year contract with Kyungbuk National University (KNU) Technopark, which is a science and technology incubation center.
The new location will position the company to enhance its pipeline of personalized medicine products and technology. In addition to developing its own pipeline, Aquavit will partner with domestic pharmaceutical firms in research, global clinical tests, and other ventures.
The city of Daegu has been expanding its commitment to the biotech and pharmaceutical industries and has invested over $ 600 million USD to date in state-of-the-art infrastructure and facilities that support the growing opportunities in these industries.
|Aquavit Life Sciences, Inc.
|Daegu, South Korea
|New R&D and Manufacturing Facility
|Phase 1 of the project
|10,000 sq. ft. space with an ISO 5 class cleanroom
|Contract Signed With
|Kyungbuk National University